Astal Laboratories Limited, a pharmaceutical company, has significantly increased its authorized share capital from Rs 20 crore to Rs 50 crore. This decision, approved by shareholders at an Extra Ordinary General Meeting (EGM) on November 6, 2025, marks a substantial expansion in the company's potential capital base.

Key Changes

The company has altered the Capital Clause V of its Memorandum of Association (MOA), resulting in the following modifications:

Corporate Action Details

• Date of Approval: November 6, 2025
• Approval Method: Extra Ordinary General Meeting
• Basis of Approval: Scrutinizer's Report dated November 6, 2025

Regulatory Compliance

Astal Laboratories Limited has duly informed the Bombay Stock Exchange (BSE) about this development on November 9, 2025. This notification aligns with the regulatory requirements under:

• Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
• Part A of Schedule III of the aforementioned regulations
• SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Company Information

• CIN: L74120UP1993PLC015605
• Registered Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
• Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

This increase in authorized share capital provides Astal Laboratories with enhanced flexibility for potential future capital raising activities, which could be crucial for the company's growth and expansion plans. However, it's important to note that this change in authorized capital does not immediately impact the company's issued share capital or market capitalization. Investors and stakeholders should monitor future announcements for any plans related to the utilization of this expanded capital base.

Astal Laboratories Limited , a pharmaceutical company, recently conducted an Extraordinary General Meeting (EGM) to address significant corporate actions. The meeting, held on November 6, 2025, via video conferencing, saw the participation of 24 members and focused on three key agenda items that could potentially reshape the company's future.

Key Highlights of the EGM

1. Increase in Authorized Share Capital: The company proposed to increase its authorized share capital and alter the capital clause of the Memorandum of Association accordingly.

2. Acquisition of Sriven Pharmachem: Astal Laboratories sought approval for acquiring a 100% stake in Sriven Pharmachem India Private Limited through an equity share swap via preferential allotment.

3. Approval of Related Party Transaction: The meeting addressed the approval of a material related party transaction for the acquisition of Sriven Pharmachem shares.

Meeting Details and Proceedings

The EGM was conducted through video conferencing, adhering to modern corporate governance practices. Dr. Radhakishore Pandrangi chaired the meeting, which began at 3:00 PM IST and concluded at 3:21 PM IST.

Key Attendees:

Voting Process and Resolutions

All resolutions were conducted through e-voting on the Central Depository Services (India) Limited (CDSL) platform. The company appointed Mr. Mahendra Prakash Khandelwal, a Practicing Company Secretary, as the scrutinizer for the e-voting process.

Resolutions Presented:

1. Increase in Authorized Share Capital (Ordinary Resolution)
2. Acquisition of Sriven Pharmachem India Private Limited (Special Resolution)
3. Approval of Material Related Party Transaction (Ordinary Resolution)

The company secretary, Mr. Mahendra Kumar, informed that the consolidated voting results would be disseminated to the stock exchange and made available on the company's website within 48 hours of the meeting's conclusion.

Implications and Next Steps

The outcomes of these resolutions could significantly impact Astal Laboratories' financial structure and market position. The proposed acquisition of Sriven Pharmachem, if approved, may expand the company's product portfolio and market reach. Meanwhile, the increase in authorized share capital could provide the company with more flexibility for future growth initiatives.

Investors and stakeholders are advised to keep an eye on the voting results and subsequent announcements from the company for a clearer picture of Astal Laboratories' strategic direction in the coming months.

As the pharmaceutical sector continues to evolve, such corporate actions may reflect Astal Laboratories' efforts to strengthen its position in the market and create value for its shareholders.